"On-line" measurement of acetylcholinesterase release from the substantia nigra of the freely-moving guinea-pig

Characterization of a Bioactive Peptide T14 in the Human and Rodent Substantia Nigra: Implications for Neurodegenerative Disease

The substantia nigra is generally considered to show significant cell loss not only in Parkinson's but also in Alzheimer's disease, conditions that share several neuropathological traits. An interesting feature of this nucleus is that the pars compacta dopaminergic neurons contain acetylcholinesterase (AChE). Independent of its enzymatic role, this protein is released from pars reticulata dendrites, with effects that have been observed in vitro, ex vivo and in vivo. The part of the molecule responsible for these actions has been identified as a 14-mer peptide, T14, cleaved from the AChE C-terminus and acting at an allosteric site on alpha-7 nicotinic receptors, with consequences implicated in neurodegeneration. Here, we show that free T14 is co-localized with tyrosine hydroxylase in rodent pars compacta neurons. In brains with Alzheimer's pathology, the T14 immunoreactivity in these neurons increases in density as their number decreases with the progression of the disease. To explore the functional implications of raised T14 levels in the substantia nigra, the effect of exogenous peptide on electrically evoked neuronal activation was tested in rat brain slices using optical imaging with a voltage-sensitive dye (Di-4-ANEPPS). A significant reduction in the activation response was observed; this was blocked by the cyclized variant of T14, NBP14. In contrast, no such effect of the peptide was seen in the striatum, a region lacking the T14 target, alpha-7 receptors. These findings add to the accumulating evidence that T14 is a key signaling molecule in neurodegenerative disorders and that its antagonist NBP14 has therapeutic potential.

When a trophic process turns toxic: Alzheimer's disease as an aberrant recapitulation of a developmental mechanism

Here we review the idea that Alzheimer's disease (AD) results from aberrant activation of a normal developmental mechanism. This process operates in primarily vulnerable, subcortical nuclei with a distinguishing embryological provenance: the basal rather than the alar plate. All cells are dependent for growth on calcium influx yet these neurons retain a sensitivity to trophic factors into maturity. However, as the brain matures this action becomes detrimental such that the trophic process could turn toxic if triggered in adult brain, in retaliation to an initial insult. The signalling molecule driving this trophic-toxic mechanism is a 14mer peptide (T14) that acts on the alpha-7 receptor to enhance calcium entry, inducing excitotoxicity and proliferation of the receptor, perpetuating a feedforward cycle of neurodegeneration including production of beta-amyloid and p-tau. The T14 system has been previously unrecognised as a basic biological process, yet its pharmaceutical manipulation could have valuable clinical applications.

Relationships and Interactions between Ionotropic Glutamate Receptors and Nicotinic Receptors in the CNS

Although ionotropic glutamate receptors and nicotinic receptors for acetylcholine (ACh) have usually been studied separately, they are often co-localized and functionally inter-dependent. The objective of this review is to survey the evidence for interactions between the two receptor families and the mechanisms underlying them. These include the mutual regulation of subunit expression, which change the NMDA:AMPA response balance, and the existence of multi-functional receptor complexes which make it difficult to distinguish between individual receptor sites, especially in vivo. This is followed by analysis of the functional relationships between the receptors from work on transmitter release, cellular electrophysiology and aspects of behavior where these can contribute to understanding receptor interactions. It is clear that nicotinic receptors (nAChRs) on axonal terminals directly regulate the release of glutamate and other neurotransmitters, α7-nAChRs generally promoting release. Hence, α7-nAChR responses will be prevented not only by a nicotinic antagonist, but also by compounds blocking the indirectly activated glutamate receptors. This accounts for the apparent anticholinergic activity of some glutamate antagonists, including the endogenous antagonist kynurenic acid. The activation of presynaptic nAChRs is by the ambient levels of ACh released from pre-terminal synapses, varicosities and glial cells, acting as a 'volume neurotransmitter' on synaptic and extrasynaptic sites. In addition, ACh and glutamate are released as CNS co-transmitters, including 'cholinergic' synapses onto spinal Renshaw cells. It is concluded that ACh should be viewed primarily as a modulator of glutamatergic neurotransmission by regulating the release of glutamate presynaptically, and the location, subunit composition, subtype balance and sensitivity of glutamate receptors, and not primarily as a classical fast neurotransmitter. These conclusions and caveats should aid clarification of the sites of action of glutamate and nicotinic receptor ligands in the search for new centrally-acting drugs.

A peptide derived from the C-terminal region of acetylcholinesterase modulates extracellular concentrations of acetylcholinesterase in the rat substantia nigra

It is well established that acetylcholinesterase (AChE) has 'non-classical' functions independent of cholinergic transmission. A region of AChE distinct from the catalytic site may be responsible for these actions via a 14-residue peptide located between residues 586-599 at the C-terminus of human AChE. This AChE-peptide possesses a high amino acid sequence homology with a region of amyloid precursor protein and shares many biophysical and physiological characteristics. In this study, the effect of AChE-peptide (AEFHRWSSYMVHWK) on the extracellular levels of endogenous AChE was examined in rat substantia nigra in vitro. A chemiluminescent assay was used to continuously measure the soluble AChE concentration from tissue punches of the substantia nigra. Application of NMDA evoked an increase in extracellular AChE levels consistent with previous results obtained from in vivo models. AChE-peptide, when applied alone, had no effect on AChE release: however, when co-applied with NMDA, AChE-peptide reduced the effectiveness of NMDA to evoke release of AChE. These results indicate, in a region of the brain central to the aetiology of Parkinson's disease, that an AChE-peptide fragment derived from AChE displays a bioactivity that could involve regulation of Ca(2+) availability and hence the release of AChE.

Behavioural correlates of the release and subsequent action of acetylcholinesterase secreted in the substantia nigra

Acetylcholinesterase is secreted in the central nervous system (independently of cholinergic transmission) in a non-classic, non-enzymatic capacity. A light-emitting reaction has recently been established that demonstrates release of this protein from the substantia nigra of a guinea pig with a temporal resolution corresponding to real time, i.e. 'on-line'. In this study the technique has been applied to investigate the significance of this novel phenomenon in the generation of specific types of movement. During locomotion a 'pulsatile' release of acetylcholinesterase occurs much more frequently than in other situations. However, these pulses of released acetylcholinesterase are of shorter duration than the respective periods of locomotion that caused them. Furthermore, as episodes of movement are repeated, the release of acetylcholinesterase becomes less likely. These observations suggest that the phenomenon does not simply reflect ongoing movement. Indeed, chewing behaviour is frequently initiated when acetylcholinesterase release occurs during locomotor activity. Hence, acetylcholinesterase released in association with locomotion may favour the onset of further types of movement.

Structural roles of acetylcholinesterase variants in biology and pathology

Apart from its catalytic function in hydrolyzing acetylcholine, acetylcholinesterase (AChE) affects cell proliferation, differentiation and responses to various insults, including stress. These responses are at least in part specific to the three C-terminal variants of AChE which are produced by alternative splicing of the single ACHE gene. 'Synaptic' AChE-S constitutes the principal multimeric enzyme in brain and muscle; soluble, monomeric 'readthrough' AChE-R appears in embryonic and tumor cells and is induced under psychological, chemical and physical stress; and glypiated dimers of erythrocytic AChE-E associate with red blood cell membranes. We postulate that the homology of AChE to the cell adhesion proteins, gliotactin, glutactin and the neurexins, which have more established functions in nervous system development, is the basis of its morphogenic functions. Competition between AChE variants and their homologs on interactions with the corresponding protein partners would inevitably modify cellular signaling. This can explain why AChE-S exerts process extension from cultured amphibian, avian and mammalian glia and neurons in a manner that is C-terminus-dependent, refractory to several active site inhibitors and, in certain cases, redundant to the function of AChE-like proteins. Structural functions of AChE variants can explain their proliferative and developmental roles in blood, bone, retinal and neuronal cells. Moreover, the association of AChE excess with amyloid plaques in the degenerating human brain and with progressive cognitive and neuromotor deficiencies observed in AChE-transgenic animal models most likely reflects the combined contributions of catalytic and structural roles.

Rat locomotion and release of acetylcholinesterase

In the substantia nigra acetylcholinesterase is released from the dopamine cells of the pars compacta independent of cholinergic transmission. In this study the effects of local and systemic amphetamine treatment were compared on acetylcholinesterase release in the rat substantia nigra in relation to concomitant behavior. Acetylcholinesterase release, measured "on-line" with a sensitive chemiluminescent system, was enhanced by amphetamine stimulation administered locally and could not be dissociated from simultaneous amphetamine-induced circling behavior. On the other hand, amphetamine administered systemically resulted in a general increase in locomotor behavior followed by a subsequent increase in acetylcholinesterase release. The alternative scenario of an initial rise in acetylcholinesterase release, subsequently followed by enhanced movement, was never seen. Hence, movement can enhance release of acetylcholinesterase from the substantia nigra, whereas "upstream" local nigral events can affect acetylcholinesterase release and movement simultaneously.

The spontaneous release of acetylcholinesterase in rat substantia nigra is altered by local changes in extracellular levels of dopamine

Acetylcholinesterase release in the guinea-pig substantia nigra has been previously investigated 'on-line', using a sensitive chemiluminescent system. Since histological observations suggest that there is a difference in acetylcholinesterase distribution in the rat substantia nigra compared to that of the guinea-pig, the first aim of the present study was to use this chemiluminescent method to characterise acetylcholinesterase release in this brain region of the freely moving rat, and the second was explore the relationship between acetylcholinesterase release and dopamine systems in this region. Accordingly, acetylcholinesterase release in the rat substantia nigra was studied under basal conditions of spontaneous release and following the local administration of (a) elevated potassium ions (30, 45, 60'mM), (b) a stimulator of dopamine/acetylcholinesterase release-D-amphetamine (10(-7), 10(-6) and 10(-5) M), (c) an inhibitor of dopamine uptake-GBR12909 (10(-7), 10(-6) and 10(-5) M). Spontaneous release of acetylcholinesterase in this brain region of the rat appears to be comparable with that observed in the guinea-pig, despite the smaller number of acetylcholinesterase-containing neurones. Furthermore, not only elevated potassium ions, but D-amphetamine as well as GBR12909, all produced significant increases in the percentage spontaneous release of acetylcholinesterase. Thus, the release of acetylcholinesterase in this region may be triggered by levels of dopamine outside of the neurone.

Glycine effects on glutamate-receptor elicited acetylcholinesterase release from slices and synaptosomes of the spinal ventral horn

To study the mechanisms by which glutamate-elicited acetylcholinesterase release (GEAR) might play a part in the pathogenesis of excitotoxically triggered motor neurone disease, and to investigate the interaction of GEAR with spinal glycinergic mechanisms, we measured acetylcholinesterase (AChE) and cholinergic markers, after stimulating ventral horn slices and synaptosomes from the mouse spinal cord, with both glutamate- and glycine-receptor agonists. Glutamate (GLU), kainate and AMPA, as well as glycine (GLY) evoked dose-related, calcium-dependent liberation of soluble forms of AChE from both slices and synaptosomes. GLY-evoked AChE release showed remarkable age-related postnatal changes. In the immature slice of the ventral horn. GLY potentiated the GEAR response in the presence of strychnine, suggesting N-methyl-D-aspartate (NMDA) receptor involvement, and was also able to evoke a strychnine-sensitive AChE release in the absence of exogenous GLU. After the 28th postnatal day, nearly all the AChE secreted was released either after the activation of non-NMDA glutamate receptors or by strychnine-sensitive GLY-evoked AChE release mechanisms. Both GEAR and GLY-evoked AChE release might impair the negative feedback loop which modulates the overactivation of motor neurones, and cause prolonged extracellular rises of soluble AChE. These effects might augment the vulnerability of motor neurones to excitotoxic stress, promote fiber outgrowth, and eventually accelerate the metabolic exhaustion of lower motor neurones. It is possible that the mechanisms described are operative at the spinal cord of ALS/MND patients.

Differential release of acetylcholinesterase in vivo, from the guinea pig substantia nigra compared to the caudate putamen following dopamine depletion

In the substantia nigra acetylcholinesterase may have a novel role unrelated to acetylcholine but linked instead to dopamine. Using a sensitive chemiluminescent system, we have investigated the effects of dopamine depletion on the vivo release of acetylcholinesterase in both the substantia nigra and the caudate putamen. Dopamine levels in the caudate putamen were significantly depleted compared to the non-lesioned side, using either of two different toxins for dopaminergic nigrostriatal cells: 6-hydroxydopamine ( 1 or 3 weeks prior to study) or N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (1 week prior to study). Spontaneous release of acetylcholinesterase from the substantia nigra was significantly reduced following all three pretreatments; however, in the caudate putamen a significant reduction in the spontaneous release of acetylcholinesterase, compared to controls, was only seen in animals studied 1 week after the administration of 6-hydroxydopamine. In all control groups, application of potassium ions (60 mM) evoked a significant release of acetylcholinesterase in the substantia nigra (p < 0.05) and this effect persisted in the surviving neurones following a partial lesion by neurotoxin pre-treatment. The results from this study are discussed in the light of a regulatory mechanism for acetylcholinesterase release from the striatum, which may come into operation depending on the extent of destruction of dopaminergic nigrostriatal neurones.

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease

The cholinesterases are members of the serine hydrolase family, which utilize a serine residue at the active site. Acetylcholinesterase (AChE) is distinguished from butyrylcholinesterase (BChE) by its greater specificity for hydrolysing acetylcholine. The function of AChE at cholinergic synapses is to terminate cholinergic neurotransmission. However, AChE is expressed in tissues that are not directly innervated by cholinergic nerves. AChE and BChE are found in several types of haematopoietic cells. Transient expression of AChE in the brain during embryogenesis suggests that AChE may function in the regulation of neurite outgrowth. Overexpression of cholinesterases has also been correlated with tumorigenesis and abnormal megakaryocytopoiesis. Acetylcholine has been shown to influence cell proliferation and neurite outgrowth through nicotinic and muscarinic receptor-mediated mechanisms and thus, that the expression of AChE and BChE at non-synaptic sites may be associated with a cholinergic function. However, structural homologies between cholinesterases and adhesion proteins indicate that cholinesterases could also function as cell-cell or cell-substrate adhesion molecules. Abnormal expression of AChE and BChE has been detected around the amyloid plaques and neurofibrillary tangles in the brains of patients with Alzheimer's disease. The function of the cholinesterases in these regions of the Alzheimer brain is unknown, but this function is probably unrelated to cholinergic neurotransmission. The presence of abnormal cholinesterase expression in the Alzheimer brain has implications for the pathogenesis of Alzheimer's disease and for therapeutic strategies using cholinesterase inhibitors.

Release of acetylcholinesterase from guinea-pig substantia nigra: effects of tryptaminergic drugs and dorsal raphé nucleus stimulation

The guinea-pig substantia nigra receives a 5-hydroxytryptaminergic (5-HT ergic) projection from the dorsal raphé nucleus. In this study we have attempted to identify the 5-HT receptor subtype mediating release of acetylcholinesterase (AChE) from nigral neurones, measured by assay of perfusate obtained via chronically implanted push-pull cannulae. The effects of direct nigral application of 5-HT, 2-methyl-5-HT and 5-methoxytryptamine. Application of submicromolar concentrations of 5-HT, 2,5,-dimethoxy-4- iodoamphetamine and alpha-methyl-5-HT significantly enhanced release of AChE, whereas 5-carboxamidotryptamine, sumatriptan, 2-methyl-5-HT and 5-methoxytryptamine were ineffective at a similar concentration range. Electrical stimulation (50 Hz, 20-300 mu A) of the dorsal raphé nucleus evoked release of AChE from the substantia nigra, and induced a rotational behavioural effect for the duration of stimulation. Pretreatment with 5,7,-dihydroxytryptamine inhibited both DRN-evoked release of AChE and animal rotation. The 5-HT receptor antagonists ketanserin and ritanserin (10(-7)-10(-6)M, when applied to the substantia nigra, inhibited raphé-stimulated AChE release. Drugs which inhibited raphé-stimulated release of AChE had no effect on concomitant animal rotation, indicating that the behavioural events are mediated via distinct processes, unrelated to those mediating nigral AChE release. The data suggest that evoked release of AChE from the substantia nigra by stimulation of the dorsal raphé nucleus may be mediated in part via a 5-HT2 receptor type. The 5-HT1D agonists 5-carboxamidotryptamine (10(-6)M and sumatriptan (10(-5)M also inhibited raphé-evoked AChE release, suggesting a possible presynaptic autoinhibitory role for 5-HT1D receptors on raphé-nigral nerve terminals.

Uptake of acetylcholinesterase by neurons in the substantia nigra

It is known that acetylcholinesterase is secreted by the dopaminergic neurons of the substantia nigra and has a subsequent action independent of cholinergic transmission. Although non-cholinergic actions of this protein have been demonstrated, the subsequent fate of acetylcholinesterase is unknown. One possibility is that acetylcholinesterase is taken up following secretion into the extracellular space. This hypothesis has been tested in vivo, in both conscious and anaesthetized guinea-pigs. Exogenous acetylcholinesterase (2-20 pM) was infused via a push-pull cannula implanted into either the substantia nigra or the surrounding extranigral regions: the amount subsequently recovered in the perfusate was then compared with control values. Only when the push-pull cannulae were implanted in the substantia nigra was there a marked decrease in the amount of acetylcholinesterase recovered; this selective retention was abolished when the perfusion medium was cooled to 4 degrees C or when the experiment was performed post mortem. Direct visualization of immunocytochemically identified nigral dopaminergic cells revealed co-localized deposits of labelled, exogenous acetylcholinesterase. Moreover, when exogenous acetylcholinesterase was boiled to prevent detection by the assay system and to eliminate any classical enzymatic action, an enhancement in perfusate levels of endogenous acetylcholinesterase was observed from nigral but not from extranigral sites, indicating that endogenous and exogenous acetylcholinesterases were in competition. These results suggest that, within the substantia nigra, secreted acetylcholinesterase may be subject to a temperature- and energy-dependent uptake mechanism.

Anatomical analysis of the neurons expressing the acetylcholinesterase gene in the rat brain, with special reference to the striatum

The localization of the neurons expressing the acetylcholinesterase gene in the rat central nervous system was studied by in situ hybridization. The striatal and nigral neurons containing acetylcholinesterase messenger RNA were especially identified. Acetylcholinesterase messenger RNA was detected in numerous areas of the central nervous system, including cholinergic areas, like striatum, nucleus basalis of Meynert, septum and diagonal band of Broca, but also non-cholinergic areas, like the cerebral cortex, the hippocampus, the cerebellum and the raphe dorsalis. In the striatum, 75% of the neurons expressing the acetylcholinesterase gene were identified as cholinergic neurons and 25% as somatostatin-producing neurons. All dopaminergic neurons of the substantia nigra pars compacta and ventral tegmental area were demonstrated to express the acetylcholinesterase gene. Our results suggest that several neuronal populations could contribute to the presence of acetylcholinesterase in the striatum: the striatal cholinergic and somatostatin-containing interneurons, the nigral dopaminergic neurons and other neurons that may be the corticostriatal, thalamostriatal and raphe-striatal neurons. This demonstrates that, especially in the striatum, acetylcholinesterase is not a specific marker of the cholinergic neurons. The diversity of the origins of striatal acetylcholinesterase suggests a multiplicity of functions for this enzyme: besides its cholinolytic actions, it may also possibly play a non-cholinolytic role in neuromodulation.

The release of acetylcholinesterase in vivo is regulated by dopaminergic systems in the guinea-pig substantia nigra

Acetylcholinesterase (AChE) and dopamine are both stored and released from dendrites within the substantia nigra: however, it is as yet unknown whether the regulation of these two purported neuromodulators is in any way related. Using a sensitive chemiluminescent system to monitor AChE release 'on-line', the effects of inhibiting synthesis and storage of dopamine with alpha-methyl-p-tyrosine (AMPT: 250 mg/kg, i.p.) and reserpine (6 mg/kg, i.p.), respectively, have been studied. Both these agents significantly reduced nigral tissue dopamine levels by decreases of 83% and 63%, respectively; however, only AMPT had a significant effect in vivo on the spontaneous release of AChE compared to conscious control animals (66% decrease). Co-application of both AMPT and reserpine resulted in a significant decrease in the tissue dopamine content (95%) and in spontaneous release of AChE compared to conscious control guinea-pigs (72%); however, these effects were not significantly different from when AMPT was employed alone. Application of potassium ions (60 mM) or veratridine (100 microM) both evoked release of AChE in control animals: however, when expressed as a percentage of basal levels, this increase in release was not influenced by drug treatment or state of consciousness. These results suggest that de novo dopamine synthesis may at least in part, have an influential effect on release (and possibly storage) of AChE in the substantia nigra.

Histochemical localization of acetylcholinesterase in the lateral eye and brain of Limulus polyphemus: might acetylcholine be a neurotransmitter for lateral inhibition in the lateral eye?

The distribution of acetylcholinesterase (AChE) in the lateral eye and brain of the horseshoe crab was investigated with histochemical means using standard controls to eliminate butyrylcholinesterase and nonspecific staining. Intense staining was observed in the neural plexus of the lateral compound eye, in the lateral optic nerve, and in various neuropils of the brain. Nerve fibers with moderate to weak staining were widespread in the brain. No somata were stained in either the lateral eye or the brain. The distribution of acetylcholinesterase in the supraesophageal ganglia and nerves of the giant barnacle was also investigated for comparison. Although both the median optic nerve of the barnacle and the lateral optic nerve of the horseshoe crab appear to contain the fibers of histaminergic neurons, only the lateral optic nerve of the horseshoe crab shows AChE staining. Other parts of the barnacle nervous system, however, showed intense AChE staining. These results along with the histochemical controls eliminate the possibility that some molecule found in histaminergic neurons accounted for the AChE staining but support the possibility that acetylcholine might be involved as a neurotransmitter in lateral inhibition in the horseshoe crab retina. Two reasonable neurotransmitter candidates for lateral inhibition, histamine and acetylcholine, must now be investigated.

The subthalamo-nigral pathway regulates movement and concomitant acetylcholinesterase release from the substantia nigra

Within the substantia nigra acetylcholinesterase is released independently of cholinergic transmission: this release could be related to some aspects of motor control. To investigate this possibility, acetylcholinesterase release was continuously monitored in relation to specific movements evoked by central electrical stimulation. Increased intensities of stimulation of the subthalamic nucleus in awake guinea-pigs produced a behavioural response, ranging from a decrease in spontaneous movement, to chewing, to both chewing and circling movements. Enhancement of acetylcholinesterase release occurred only when large scale movements (circling as well as chewing) were evoked by subthalamic stimulation: however, a similar protocol of stimulation during ketamine-induced anaesthesia did not produce any comparable movements nor any concomitant change in the release of acetylcholinesterase. Perfusion of the glutamate agonist N-methyl-D-aspartate (NMDA) into the substantia nigra also induced an increase in release of acetylcholinesterase from the substantia nigra of conscious animals, whereas (S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) did not significantly enhance acetylcholinesterase levels. It is concluded that AChE release in the substantia nigra can occur as a result of activation of glutamatergic subthalamic afferents, and that this activation may also be associated with changes in movement.

Secreted acetylcholinesterase: non-classical aspects of a classical enzyme

Recent evidence suggests that termination of cholinergic transmission is just one of the many ways in which acetylcholinesterase (AChE) could influence neuronal function. Neuronal AChE can be secreted from several brain regions, while purified AChE possesses several properties (in addition to its cholinesterase activity) that can affect neuronal function, including the abilities to influence certain membrane conductances, enhance excitatory amino acid transmission and hydrolyse peptides. Loss of AChE and its non-classical actions would have a profound effect on brain function in neurodegenerative diseases such as Alzheimer's disease where there is widespread loss of AChE-containing neurons.

The relationship between visual stimulation, behaviour and continuous release of protein in the substantia nigra

In the substantia nigra, a protein (acetylcholinesterase) is secreted from the dendrites of dopaminergic pars compacta neurons, in a noncholinergic capacity. This non-classical phenomenon could be influenced by sensory stimulation: the effect of light flashing was investigated on the 'on-line' release of acetylcholinesterase and concomitant behaviour in the guinea-pig. The stimulus induced an increase in release of the protein and the appearance of chewing movements. Similarly, chewing could also be elicited by direct local application of exogenous acetylcholinesterase. The results suggest that visual stimulation causes release of AChE, which in turn facilitates movement. Therefore secretion of this protein within the substantia nigra might form an important intermediary step in visuo-motor interactions.